The lowered price target from $20 to $15 by a major financial institution like Goldman Sachs is likely to have a negative short-term impact on Dynavax Technologies' stock price. The Neutral rating suggests no strong buy or sell recommendation, but the reduced price target indicates a less optimistic outlook.